KBI BioPharma

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

Comera Life Sciences, formerly known as ReForm Biologics, is a biotechnology company focused on developing advanced formulation technologies for biotherapeutics. Founded in 2014 and based in Woburn, Massachusetts, the company specializes in creating patented, FDA-friendly excipients that enhance the stability and administration of therapeutic biologics. Comera's proprietary platforms enable pharmaceutical companies to produce life-saving medications that are easier to administer, less immunogenic, and more efficient to manufacture, ultimately improving treatment options for fragile patients.

Elion Labs is a contract services organization that specializes in analytical development and product characterization for the biopharmaceutical industry. The company provides a wide range of services, including analytical method development, qualification and validation, and analytical characterization testing of biologics. Additionally, Elion offers formulation development, training in specialized analytical techniques, and comprehensive data analysis that includes visualization and interpretation of complex datasets. The organization also engages in technical and regulatory writing, as well as technical consulting, ensuring that clients receive high-quality support tailored to their specific needs. Elion Labs is dedicated to delivering its services with professionalism, quality, and efficiency.

GlycoSeLect specialises in the development and production of Recombinant Prokaryotic Lectins (RPLs), enhanced tools for the analysis and selective purification of glycosylated biomolecules. RPLs have a broad spectrum of applications across the life sciences in: - Basic R&D – Glycobiology & Glycoproteomics. - Biomarker Discover & Biomedical Diagnostics. - The Biopharmaceutical Industry. - Vaccines - Cosmetics GlycoSeLect's Recombinant Prokaryotic Lectins (RPLs) present significant advantages over existing commercially available lectins products including: - Simplified, rapid & cost effective production through recombinant expression in Escherichia coli. - High purity & consistent performance. - Genetically enhanced glycan binding properties (specificity & affinity). - Scalable production facilitating utilization for large scale applications.

Alliance Protein Laboratories, Inc. is a contract research and consulting firm based in San Diego, California, specializing in biophysical and biochemical analytical services. Founded in 1998, the company focuses on protein and peptide biophysical characterization, protein aggregation, purification, and stabilization. It also provides contract purification services at the research scale and offers analytical techniques such as analytical ultracentrifugation and concentration-gradient multi-angle light scattering. As of June 2018, Alliance Protein Laboratories operates as a subsidiary of KBI Biopharma Inc.

Aeglea BioTherapeutics is a clinical-stage biotechnology company focused on developing human enzyme therapeutics for rare genetic and cancer diseases. Its lead product candidate, pegzilarginase, is a recombinant human Arginase 1 enzyme currently undergoing Phase III trials to assess its safety and efficacy in treating Arginase 1 deficiency. The company's preclinical pipeline includes several innovative candidates: ACN00177 for homocystinuria, AEB5100 which degrades plasma cystine and cysteine, AEB2109 targeting the degradation of methionine, and AEB3103. Aeglea BioTherapeutics aims to exploit the amino acid dependencies of tumors by creating novel, human-derived enzymes that selectively target these vulnerabilities, differentiating the metabolic needs of tumor cells from those of normal tissues. Founded in 2013 and headquartered in Austin, Texas, the company was formerly known as Aeglea BioTherapeutics Holdings, LLC before changing its name in 2015.